Related Experiment Video
Updated: Sep 18, 2025
A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
Synergy Assay for Screening Small Molecule Combinations in Brain Cancer Stem Cells
Benjamin Brakel1,2, Iqra Chaudhry1,2, Chitra Venugopal1,3
1Centre for Discovery in Cancer Research, McMaster University, Hamilton, ON, Canada.
Abstract:
Brain tumors are among the most heterogeneous tumors characterized. This heterogeneity drives resistance to single-drug therapies, making combination treatment a more promising approach to improve treatment outcomes. To optimize drug combinations and guide treatment development in this new era of combinatorial therapy, methods for quantifying synergistic, additive or antagonistic interactions between treatments are needed. In this chapter, we describe an in vitro assay to identify synergistic drug combinations in brain-tumor-derived cell cultures. As the gold-standard assay for the in vitro evaluation of drug combination efficacy, this protocol is a fast, inexpensive, and highly reproducible method for identifying and validating synergistic drug combinations.
Insights
Brain tumor heterogeneity necessitates combination therapies. This study presents a fast, inexpensive in vitro assay to identify synergistic drug combinations, improving brain tumor treatment strategies.
Area of Science:
- Oncology
- Pharmacology
- Biotechnology
Background:
- Brain tumors exhibit significant heterogeneity, contributing to resistance against single-agent therapies.
- Combination treatments offer a more promising strategy for improving therapeutic outcomes in brain tumors.
- Quantifying drug interactions (synergistic, additive, antagonistic) is crucial for optimizing combinatorial therapy.
Purpose of the Study:
- To describe an in vitro assay for identifying synergistic drug combinations.
- To provide a method for validating drug efficacy in brain tumor treatment.
Main Methods:
- Development and description of an in vitro assay using brain-tumor-derived cell cultures.
- Evaluation of drug combination interactions.
Main Results:
- The described assay is a fast, inexpensive, and highly reproducible method.
- The assay effectively identifies and validates synergistic drug combinations.
Conclusions:
- This protocol serves as a gold-standard for in vitro evaluation of drug combination efficacy.
- The assay facilitates the optimization of drug combinations for improved brain tumor treatment.
More Related Videos
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
07:51High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
Published on: May 21, 2018